By Jonathan Gardner
Published May 18, 2026
In a high-stakes move to secure its long-term market dominance, Merck & Co. announced positive clinical trial results on Monday for Sac-TMT, a promising cancer therapy originating from its strategic partnership with Chinese biotech firm Kelun. The data, which demonstrated significant improvements in patient outcomes for those suffering from advanced endometrial cancer, marks the first successful readout from a massive, 17-study development program. As Merck faces the looming patent expiration of its powerhouse immunotherapy Keytruda, the success of Sac-TMT serves as a vital proof-of-concept for the company’s ambitious $70 billion annual revenue goal for the next decade.
The Core Developments: A Breakthrough in Endometrial Cancer
The Phase 3 trial data released on May 18, 2026, focused on patients whose endometrial cancer had continued to progress despite undergoing standard-of-care treatments, including platinum-based chemotherapy and prior immunotherapy regimens such as Keytruda.
According to the preliminary readout, Sac-TMT demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) when compared to conventional chemotherapy options. Furthermore, patients treated with the drug exhibited higher rates of durable remission.
While Merck has not yet released the granular, raw data—which is slated for a formal presentation at the upcoming American Society of Clinical Oncology (ASCO) conference—the clinical signal is clear: Sac-TMT is a potent weapon against TROP2-expressing tumors. TROP2, a cell-surface protein, is frequently overexpressed in a variety of aggressive solid tumors, making it a "holy grail" target for precision oncology.
Chronology: From Chinese Laboratories to Global Trials
The journey of Sac-TMT is emblematic of the shifting landscape in global pharmaceutical R&D, where Western giants are increasingly looking toward China for innovative drug candidates.
- Early 2020s: As the global oncology market matured, Merck began identifying a "post-Keytruda cliff." Recognizing that no single drug could replace the multifaceted utility of its flagship immunotherapy, the company pivoted toward a "portfolio" strategy.
- The Kelun Alliance: Merck entered into a wide-ranging, multi-asset licensing agreement with Sichuan Kelun-Biotech. This partnership was designed to grant Merck access to seven of Kelun’s proprietary antibody-drug conjugates (ADCs)—a class of drugs often described as "biological missiles" that deliver toxic chemotherapy payloads directly to cancer cells.
- 2024–2025: Sac-TMT rapidly progressed through Phase 1 and 2 trials, showing a safety profile that was manageable for patients, a common hurdle for ADCs.
- May 2026: The current endometrial cancer trial reaches its primary endpoint, marking the first of 17 pivotal studies that will dictate the drug’s commercial viability across a spectrum of oncology indications, including breast and lung cancers.
Supporting Data and Analyst Outlook
The enthusiasm from the scientific and financial community is palpable. RBC Capital Markets analyst Trung Huynh noted that the data provided an "encouraging reinforcement" of the drug’s safety profile, which has been a primary concern for developers of TROP2-targeted ADCs in the past.
Financial models suggest that Sac-TMT is not just a clinical success, but a fiscal necessity. Huynh forecasts that the drug will generate approximately $2.6 billion in sales by 2030, with that figure accelerating to $7.2 billion by 2034. These projections are predicated on the drug securing approvals across multiple solid tumor indications, effectively positioning it as a cornerstone of the next generation of Merck’s oncology pipeline.
The "17-study program" is designed to create a "basket" of approvals. By testing the drug across diverse tissue types, Merck is attempting to replicate the versatility that made Keytruda the top-selling drug in history. If the remaining 16 trials show results consistent with the endometrial cancer study, Sac-TMT could become a new standard of care in the latter half of the decade.
Official Responses and Strategic Implications
Merck’s leadership has remained cautiously optimistic, framing the data as a validation of their business development strategy.
"The results from our endometrial cancer trial confirm that our collaborative approach with Kelun is yielding tangible, life-saving benefits for patients who have exhausted all other options," a company spokesperson stated. "This is a pivotal step in our multi-pronged oncology strategy, ensuring that Merck remains at the forefront of cancer care long after our current portfolio transitions."
The broader industry implications are equally significant. For years, there has been skepticism regarding the "China-to-West" licensing model, with concerns about regulatory alignment and manufacturing consistency. The success of Sac-TMT serves as a definitive counter-narrative, proving that Chinese-developed assets can successfully navigate the rigors of U.S. and European clinical regulatory pathways.
The Post-Keytruda Future: A $70 Billion Ambition
The stakes for Merck are existential. Keytruda has been a runaway success, winning approvals for 19 different cancer types and two "tissue-agnostic" indications—meaning it can be used for any cancer with a specific genetic signature, regardless of where it originated in the body.
However, patent cliffs are inevitable. To maintain its $70 billion annual sales target, Merck cannot rely on a single "hero drug." Instead, it is building a modular pipeline. Sac-TMT represents the "ADC pillar" of this strategy. Alongside this, Merck continues to invest in mRNA cancer vaccines, bispecific antibodies, and targeted inhibitors.
The Role of ASCO
The oncology community is now turning its attention to the upcoming ASCO annual meeting. Industry experts expect that the detailed data presentation will clarify several key questions:
- Dose-Limiting Toxicities: How does the drug perform in larger, more diverse patient populations?
- Combination Therapy Potential: Can Sac-TMT be safely combined with other immunotherapy agents to enhance efficacy?
- Regulatory Timeline: Does this data package provide enough evidence for an accelerated FDA filing?
Conclusion
As the data from the 17-study program continues to emerge, the pharmaceutical world will be watching closely. Sac-TMT is more than just a new treatment; it is the vanguard of Merck’s future. If the company can successfully translate these results into widespread clinical adoption, it will have successfully navigated one of the most dangerous transitions in modern pharmaceutical history.
For patients, the results offer a glimmer of hope where there was previously little. For Merck, the results offer the financial stability required to continue the search for the next, even more effective, generation of cancer therapies. The success of Sac-TMT is a testament to the power of global scientific collaboration and the relentless pace of innovation in the fight against one of humanity’s most persistent adversaries.
About the Author
